| Literature DB >> 33588732 |
Syed Sayeed Ahmad1, Mohammad Khalid2, Mohammad A Kamal3, Kaiser Younis4.
Abstract
BACKGROUND: Alzheimer's disease (AD) affects several people worldwide and has devastating impacts on society with a limited number of approaches for its pharmacological treatment. The main causes of AD are not clear yet. However, the formation of senile plaques, neurofibrillary tangles, hyper-phosphorylation of tau protein, and disruption of redox homeostasis may cause AD. These causes have a positive correlation with oxidative stress, producing reactive ions, which are responsible for altering the physiological condition of the body.Entities:
Keywords: Alzheimer's disease; mechanism of AChE in Alzheimer's disease.; nutraceuticals; nutrients; phytochemicals
Mesh:
Substances:
Year: 2021 PMID: 33588732 PMCID: PMC9185787 DOI: 10.2174/1570159X19666210215122333
Source DB: PubMed Journal: Curr Neuropharmacol ISSN: 1570-159X Impact factor: 7.708
Fig. (1)Mechanism of AChE in Alzheimer disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Role of alkaloid compounds in Alzheimer’s disease.
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|
| 1 | Aromoline |
| Showed significant human BChE (hBChE) inhibitory activity. | [ | |||
| 2 | Berberine | Alzheimer’s like disease was induced in rats orally by a mixture of aluminum, cadmium, and fluoride | Improved cognitive behaviors and Docking results showed that berberine inhibited AChE, COX-2, and TACE. | [ | |||
| 3 | Berberine | Aβ25-35 induced apoptosis in primary neuron cells isolated from the hippocampus of newborn mice | Berberine reversed the effects induced by Aβ25-35. | [ | |||
| 4 | Berberine loaded multiwalled carbon nanotubes with polysorbate and phospholipid coating | Improvement in the rate and extent of drug absorption in the plasma and brain tissues. | [ | ||||
| 5 | Berberine | Ethanol-induced oxidative stress and memory dysfunction in rats | Prevents changes in oxidative stress and cholinesterase activity. | [ | |||
| 6 | Berberine | Synaptic deficits induced by D-galactose in Male Wistar rats | Synaptic/memory impairments. | [ | |||
| 7 | Berberine | Twenty-month-old male | Alleviate postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. | [ | |||
| 8 | Berberine | Diabetic neuropathy induced by streptozotocin and a high-carbohydrate/high-fat diet in rats. | Beneficial against diabetic neuropathy induced by streptozotocin and a high-carbohydrate/high-fat diet in rats. | [ | |||
| 9 | Dehydroevodiamine | Rat brain slices | It activates a | [ | |||
| 10 | Galantamine | Oral tremor induced by | Significantly attenuated the tremulous jaw movements | [ | |||
| 11 | Galantamine hydrobromide | Chronic effects of Galantamine hydrobromide on male albino mice. | Galantamine hydrobromide exerted severe perturbations in the cholinergic system in all regions of the brain on chronic exposure, thus eventually leading to behavioral changes. | [ | |||
| 12 | Galantamine attaching to ceria-containing hydroxyapatite as well ceria-containing | Ovariectomized AD | Nanoceria-containing uncoated hydroxyapatite-based-galantamine nanocomposite had been found a highly efficient anti-Alzheimer agent, where the nanoceria and hydroxyapatite also showed noteworthy useful effects to galantamine on drug-delivering action, scavenging the hazard reactive oxygen species, repairing the degenerated nerve cells, and discarding the toxic Aβ-amyloid plaques. | [ | |||
| 13 | Galantamine | AD model mice | Administration of galantamine from the preplaque phase ameliorates the memory decline, improved the unbalanced redox state, and enhanced microglial function. | [ | |||
| 14 | Huperzine A | Alzheimer Transgenic Mouse Model | It reduces the level of Aβ. | [ | |||
| 15 | Huperzine C |
| Showed moderate AChE inhibition with an | [ | |||
| 16 | N-methylasimilobine |
| Exhibited 50% inhibition of AChE at the concentration of | [ | |||
| 17 | Isorhynchophylline | Amyloid-β Induced Cognitive Impairment in Rats | It restores Aβ -induced | [ | |||
|
|
|
|
|
| |||
| 18 | Galanthamine |
| The inhibitory potential of AChE with IC50 values was 0.35 µmol/L | [ | |||
| 19 | Palmatine | Exhibits anti-inflammatory, anti-depressive, anti-pyretic, anti-neurodegenerative properties. | [ | ||||
| 20 | Palmatine and physostigmine | Swiss young male albino mice | Palmatine and physostigmine significantly improved the learning and memory of mice | [ | |||
| 21 | Palmatine |
| Inhibit PHF6 and full-length tau aggregation and disassemble pre-formed fibrils | [ | |||
| 22 | Phenserine | Three-month-old male | Possess the AChE inhibitory activity | [ | |||
| 23 | Sanguinine |
| Inhibited the activity of AChE | [ | |||
| 24 | Taspine |
| Inhibited the activity of AChE with an IC50 value of 0.33 ± 0.07 | [ | |||
Moringa oleifera leaf extract on the aluminum-induced temporal cortical degeneration in male albino Wiastar rats. Moringa oleifera leaf extract reduced the serum aluminum concentration and fights against aluminum-induced neurohistopathology in the temporal cortex [92]. Moringa oleifera leaf extract was incubated with the primary culture of embryonic hippocampal neurons and it has been reported that the leaf extract promoted axodendritic maturation and neuroprotection, suggesting its well-being importance for the nervous system [93]. In a recent study, Moringa oleifera was tested against hyperhomocysteinemia induced AD-like pathology in rats, the results showed to prevent the oxidative stress and cognitive impairments induced by homocysteine. It has also decreased the tau hyperphosphorylation and Aβ production in the AD rat model [94]. From the above data, Moringa oleifera is well supported as a good candidate for the treatment of AD.